{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:57:50Z","timestamp":1768273070836,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,4,14]],"date-time":"2009-04-14T00:00:00Z","timestamp":1239667200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s12032-009-9218-8","type":"journal-article","created":{"date-parts":[[2009,4,13]],"date-time":"2009-04-13T14:54:47Z","timestamp":1239634487000},"page":"363-367","source":"Crossref","is-referenced-by-count":54,"title":["Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy"],"prefix":"10.1007","volume":"27","author":[{"given":"Thomas","family":"Nelius","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Klatte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"de Riese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Filleur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,4,14]]},"reference":[{"key":"9218_CR1","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/1097-0142(19930201)71:3+<1098::AID-CNCR2820711432>3.0.CO;2-G","volume":"71","author":"A Yagoda","year":"1993","unstructured":"Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993;71:1098\u2013109. doi: 10.1002\/1097-0142(19930201)71:3+<1098::AID-CNCR2820711432>3.0.CO;2-G .","journal-title":"Cancer"},{"key":"9218_CR2","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1200\/JCO.2005.12.187","volume":"23","author":"S Oudard","year":"2005","unstructured":"Oudard S, Banu E, Beuzeboc P, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol. 2005;23:3343\u201351. doi: 10.1200\/JCO.2005.12.187 .","journal-title":"J Clin Oncol"},{"key":"9218_CR3","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513\u201320. doi: 10.1056\/NEJMoa041318 .","journal-title":"N Engl J Med"},{"key":"9218_CR4","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312. doi: 10.1056\/NEJMoa040720 .","journal-title":"N Engl J Med"},{"key":"9218_CR5","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1464-410X.2006.06324.x","volume":"98","author":"T Nelius","year":"2006","unstructured":"Nelius T, Klatte T, Yap R, et al. A randomized study of docetaxel and dexamethasone with - or high-dose estramustine for patients with advanced hormone-refractory prostate cancer. BJU Int. 2006;98:580\u20135. doi: 10.1111\/j.1464-410X.2006.06324.x .","journal-title":"BJU Int"},{"key":"9218_CR6","first-page":"573","volume":"28","author":"T Nelius","year":"2005","unstructured":"Nelius T, Reiher F, Lindenmeir T, et al. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer. Onkologie. 2005;28:573\u20138. doi: 10.1159\/000088297 .","journal-title":"Onkologie"},{"key":"9218_CR7","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1111\/j.1742-1241.2007.01551.x","volume":"61","author":"S Chowdhury","year":"2007","unstructured":"Chowdhury S, Burbridge S, Harper PG. Chemotherapy for the treatment of hormone-refractory prostate cancer. Int J Clin Pract. 2007;61:2064\u201370. doi: 10.1111\/j.1742-1241.2007.01551.x .","journal-title":"Int J Clin Pract"},{"key":"9218_CR8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.biopha.2004.08.006","volume":"58","author":"A Nicolini","year":"2004","unstructured":"Nicolini A, Mancini P, Ferrari P, et al. Oral -dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed Pharmacother. 2004;58:447\u201350.","journal-title":"Biomed Pharmacother"},{"key":"9218_CR9","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.juro.2007.01.143","volume":"177","author":"R Lord","year":"2007","unstructured":"Lord R, Nair S, Schache A, et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol. 2007;177:2136\u201340. doi: 10.1016\/j.juro.2007.01.143 . discussion 2140.","journal-title":"J Urol"},{"key":"9218_CR10","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","volume":"105","author":"ME Lutsiak","year":"2005","unstructured":"Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4(+)25\u00a0+\u00a0T regulatory cell function implicated in enhanced immune response by -dose cyclophosphamide. Blood. 2005;105:2862\u20138. doi: 10.1182\/blood-2004-06-2410 .","journal-title":"Blood"},{"key":"9218_CR11","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00280-005-0163-8","volume":"58","author":"JE Damber","year":"2006","unstructured":"Damber JE, Vallbo C, Albertsson P, et al. The anti-tumour effect of -dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol. 2006;58:354\u201360. doi: 10.1007\/s00280-005-0163-8 .","journal-title":"Cancer Chemother Pharmacol"},{"key":"9218_CR12","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI9872","volume":"105","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105:1045\u20137. doi: 10.1172\/JCI9872 .","journal-title":"J Clin Invest"},{"key":"9218_CR13","first-page":"1878","volume":"60","author":"T Browder","year":"2000","unstructured":"Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878\u201386.","journal-title":"Cancer Res"},{"key":"9218_CR14","first-page":"2731","volume":"62","author":"S Man","year":"2002","unstructured":"Man S, Bocci G, Francia G, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 2002;62:2731\u20135.","journal-title":"Cancer Res"},{"key":"9218_CR15","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1158\/0008-5472.CAN-05-0765","volume":"65","author":"Y Shaked","year":"2005","unstructured":"Shaked Y, Emmenegger U, Francia G, et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res. 2005;65:7045\u201351. doi: 10.1158\/0008-5472.CAN-05-0765 .","journal-title":"Cancer Res"},{"key":"9218_CR16","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","volume":"17","author":"GJ Bubley","year":"1999","unstructured":"Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461\u20137.","journal-title":"J Clin Oncol"},{"key":"9218_CR17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3816\/CGC.2005.n.015","volume":"4","author":"KW Beekman","year":"2005","unstructured":"Beekman KW, Fleming MT, Scher HI, et al. Second-line chemotherapy for prostate cancer: patient characteristics and survival. Clin Prostate Cancer. 2005;4:86\u201390.","journal-title":"Clin Prostate Cancer"},{"key":"9218_CR18","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/cncr.11686","volume":"98","author":"B Hellerstedt","year":"2003","unstructured":"Hellerstedt B, Pienta KJ, Redman BG, et al. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. Cancer. 2003;98:1603\u201310. doi: 10.1002\/cncr.11686 .","journal-title":"Cancer"},{"key":"9218_CR19","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1200\/JCO.1995.13.6.1398","volume":"13","author":"LJ Brandes","year":"1995","unstructured":"Brandes LJ, Bracken SP, Ramsey EW. N, N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine in combination with cyclophosphamide: an active, -toxicity regimen for metastatic hormonally unresponsive prostate cancer. J Clin Oncol. 1995;13:1398\u2013403.","journal-title":"J Clin Oncol"},{"key":"9218_CR20","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/1097-0142(19810415)47:8<1949::AID-CNCR2820470806>3.0.CO;2-3","volume":"47","author":"HB Muss","year":"1981","unstructured":"Muss HB, Howard V, Richards F 2nd, et al. Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial. Cancer. 1981;47:1949\u201353. doi: 10.1002\/1097-0142(19810415)47:8<1949::AID-CNCR2820470806>3.0.CO;2-3 .","journal-title":"Cancer"},{"key":"9218_CR21","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/(SICI)1097-0142(20000315)88:6<1438::AID-CNCR23>3.0.CO;2-O","volume":"88","author":"S Bracarda","year":"2000","unstructured":"Bracarda S, Tonato M, Rosi P, et al. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study. Cancer. 2000;88:1438\u201344. doi: 10.1002\/(SICI)1097-0142(20000315)88:6<1438::AID-CNCR23>3.0.CO;2-O .","journal-title":"Cancer"},{"key":"9218_CR22","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/cncr.11713","volume":"98","author":"LM Glode","year":"2003","unstructured":"Glode LM, Barqawi A, Crighton F, et al. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer. 2003;98:1643\u20138. doi: 10.1002\/cncr.11713 .","journal-title":"Cancer"},{"key":"9218_CR23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000055296","volume":"60","author":"K Nishimura","year":"2001","unstructured":"Nishimura K, Nonomura N, Ono Y, et al. Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer. Oncology. 2001;60:49\u201354. doi: 10.1159\/000055296 .","journal-title":"Oncology"},{"key":"9218_CR24","first-page":"995","volume":"111","author":"P Albertsson","year":"2003","unstructured":"Albertsson P, Lennernas B, Norrby K. Chemotherapy and antiangiogenesis: drug-specific effects on microvessel sprouting. Apmis. 2003;111:995\u20131003. doi: 10.1111\/j.1600-0463.2003.apm1111102.x .","journal-title":"Apmis"},{"key":"9218_CR25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jcb.10772","volume":"91","author":"B Nicholson","year":"2004","unstructured":"Nicholson B, Theodorescu D. Angiogenesis and prostate cancer tumor growth. J Cell Biochem. 2004;91:125\u201350. doi: 10.1002\/jcb.10772 .","journal-title":"J Cell Biochem"},{"key":"9218_CR26","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/0008-5472.CAN-03-3126","volume":"64","author":"Y Hamano","year":"2004","unstructured":"Hamano Y, Sugimoto H, Soubasakos MA, et al. Thrombospondin-1 associated with tumor microenvironment contributes to -dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 2004;64:1570\u20134. doi: 10.1158\/0008-5472.CAN-03-3126 .","journal-title":"Cancer Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-009-9218-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-009-9218-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-009-9218-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T02:22:38Z","timestamp":1559442158000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-009-9218-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,14]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["9218"],"URL":"https:\/\/doi.org\/10.1007\/s12032-009-9218-8","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,14]]}}}